22157.jpg
Global Opioid Drugs Markets 2019-2020 & Forecast to 2028: Increased Number of Lawsuits Against the Manufacturers of Opioid Drugs Restraining Growth
September 29, 2020 06:24 ET | Research and Markets
Dublin, Sept. 29, 2020 (GLOBE NEWSWIRE) -- The "Global Opioid Drugs Market 2019-2028" report has been added to ResearchAndMarkets.com's offering. The global opioids drug market to proliferate with...
BioDelivery Sciences logo
BioDelivery Sciences Announces Five Medical Abstracts Accepted at PAINWeek® 2019 National Conference on Pain Management
August 28, 2019 07:45 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 28, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic...
BioDelivery Sciences logo
BioDelivery Sciences to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
July 30, 2019 07:45 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions,...
BioDelivery Sciences logo
BioDelivery Sciences Announces Further Improved Insurance Coverage for BELBUCA®
July 09, 2019 08:00 ET | BioDelivery Sciences International, Inc.
Regional Commercial Plans Improved Access for More Than 6 Million Lives During 2Q More Than 90% of Commercial Lives Now Have Access to BELBUCA in the U.S. RALEIGH, N.C., July 09, 2019 (GLOBE...
BioDelivery Sciences logo
BioDelivery Sciences Expands Upon Report from Pain Management Task Force
June 24, 2019 08:00 ET | BioDelivery Sciences International, Inc.
Company’s Activities Support Buprenorphine Recommendations Including: Primary Use of Buprenorphine in Chronic Pain when Clinically IndicatedHaving Payers Provide Coverage and Reimbursement for...
BioDelivery Sciences logo
BioDelivery Sciences Announces Upcoming Investor Conference Presentations
May 29, 2019 16:10 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences logo
BioDelivery Sciences Strengthens Financial Position with Debt Refinancing
May 28, 2019 16:10 ET | BioDelivery Sciences International, Inc.
New Agreement is Cash Flow Accretive, Lowers Cost of Capital and Extends Debt Maturity Reduces Annual Interest Costs by Approximately $1.5 million Increases Flexibility to Continue Growth Trajectory...
BioDelivery Sciences logo
BioDelivery Sciences Reports Strong First Quarter 2019 Results and Raises BELBUCA® Full-Year Expectations
May 06, 2019 16:05 ET | BioDelivery Sciences International, Inc.
BELBUCA® Net Sales Increased by 134% versus Prior Year to All-time High of $18.7 MillionSymproic® Acquisition and Commercial Integration Successfully CompletedCompany Raises Full-Year BELBUCA Net...
BioDelivery Sciences logo
BioDelivery Sciences to Report Fourth Quarter and Full Year 2018 Financial Results
February 21, 2019 07:45 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., Feb. 21, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences logo
BioDelivery Announces Expanded Preferred Insurance Coverage For BELBUCA®
February 04, 2019 08:03 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...